Elevar Therapeutics Evaluates Lirafugratinib in Solid Tumors with FGFR2 Alterations
A clinical trial is underway to assess the efficacy and safety of lirafugratinib in patients with solid tumors harboring FGFR2 fusion or rearrangement.
Asset / Drug
Drug and asset intelligence for lirafigratinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
FGFR Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.